On April 7, 2023, KPMG China hosted the award ceremony for “The 2nd Biotech 50 List” across Beijing, Shanghai, and Shenzhen. Shenzhen Moyuan Biotechnology Ltd. (referred to as “META Pharmaceuticals”) stood out with its distinctive research focus and boundless growth prospects. After thorough research and analysis, META Pharmaceuticals was honored as one of the “Biotechnology Innovation 50” by KPMG China and a panel of industry experts.

Organized by KPMG China and co-organized by CITIC Securities Company Limited, the second edition of the Biotechnology Innovation 50 was launched in October 2022 and spanned nearly half a year. KPMG invited external expert judges to participate in the selection process, evaluating segments such as biopharmaceuticals, medical devices, cell therapy, and gene therapy. The assessment encompassed multiple dimensions, including the leading competitiveness of product technology, the uniqueness and innovativeness of the business model, the composition of the core R&D team, financial health, and solutions to industry pain points.

This initiative aims to assist biotechnology enterprises in establishing a diversified resource docking platform, increasing market visibility, achieving organic growth from within, and further advancing innovation and high-quality development within China’s biotechnology sector.  

KPMG China’s 2nd Biotech Innovation 50 Companies List

Mr. Alex Wang, Head of Operations at META Pharmaceuticals (pictured left), expressed: “What China lacks today is the exploration of new targets and mechanisms. The jury’s recognition serves as an encouragement to META Pharmaceuticals, positioned as an explorer in the cutting-edge interdisciplinary field of immunometabolism. Our pipeline is progressing rapidly, and we are poised to initiate global clinical studies in the near future. Our goal is to swiftly bring the new generation of autoimmune disease drugs to benefit more patients.”

Dr. Cao Zhen, Head of META Pharmaceuticals’ Hong Kong office (pictured right), stated: “As a company dedicated to FIRST-IN-CLASS original drugs in the immune metabolism domain, META Pharmaceuticals is honored to be selected for the 2nd KPMG Biotech Innovator 50 list. This recognition affirms our unwavering commitment to independent innovation and acknowledges our industry partners’ innovative capabilities and market potential. META Pharmaceuticals will continue to strive diligently, contributing to the development of domestic innovative drugs worldwide and promoting the high-quality growth of China’s biopharmaceutical industry.”

As a pioneer in the emerging field of immuno-metabolism, META Pharmaceuticals has dedicated nearly a decade to exploring the intricate biological mechanisms governing the interplay between immune cells and nutrient metabolism. Our breakthrough discovery involves a therapeutic strategy that modulates immune system function by regulating the metabolic activity of immune cells. This approach holds promise for targeting and treating a wide spectrum of chronic diseases arising from immune system and metabolic system disorders. These encompass autoimmune diseases, cancer, metabolic disorders, and chronic conditions associated with aging.

Furthermore, META Pharmaceuticals is committed to constructing a diverse and differentiated drug pipeline, covering a broader range of metabolic pathways and benefiting a wider array of therapeutic indications, including cancer.

Our selection as one of KPMG China’s second biotech innovation 50 companies underscores the recognition of our work in the immunometabolism research field. META Pharmaceuticals will remain firmly rooted in this domain, persistently driving innovation, and diligently developing improved drugs to enhance the lives of millions of autoimmune disease patients worldwide.

About KPMG

Founded in 1897, KPMG is a global organization of independent professional members and is one of the world’s top accounting professional services firms, specializing in audit, tax and advisory services. It is also one of the Big Four international accounting firms.

About  META Pharmaceuticals

META Pharmaceuticals is an original drug discovery and development company with a biomedical R&D team consisting of PhDs graduated from Ivy League universities in the United States, and co-funded/technology-incubated by renowned domestic and international venture capital institutions. Located in Shenzhen Loop Shenzhen-Hong Kong Science and Technology Cooperation Zone, the company is the first original drug discovery and development company in China to be created commercially based on a new biological theory of immune metabolism.